Because Novartis thought Covid was over but then Omicron came along. As for all course ARDS the data did not support it especially when you consider the new therapies that have been developed over the last 2 years. Novartis has chosen to leave this indication as it already have cost them big time in failed trials and lost reputation of a existing drug.
This has been well disgusted here on HC apparently some posters choose not to listen.
RWE for 2nd MSB COVID-19 ARDS P3 Trial, page-111
-
- There are more pages in this discussion • 795 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.324B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $4.288M | 3.634M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 36 | 40452 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 88883 | 16 |
View Market Depth
| Last trade - 13.52pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |